Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer.

Yiting Dong,Yixiang Zhu,Minglei Zhuo,Xiaomin Chen,Yinpeng Xie,Jianchun Duan,Hua Bai,Shiguang Hao,Zicheng Yu,Yuting Yi,Yanfang Guan,Jie Yuan,Xuefeng Xia,Xin Yi,Jie Wang,Zhijie Wang

Cancers（2022）

引用 1|浏览35

暂无评分

摘要

We developed Ma-bTMB, a convenient, readily available, non-invasive predictive biomarker effectively differentiates beneficiaries of ICIs therapy in advanced NSCLC, warranting future clinical trials.

查看译文

关键词

ICIs,MSAF,NSCLC,TMB,immune checkpoint inhibitors,maximum somatic allele frequency,non-small-cell lung cancer,tumor mutation burden

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要